The Innovation Ecosystem includes six critical components
Target ALS fosters collaboration by exclusively funding multi-investigator research consortia that pursue novel approaches in ALS drug discovery and development.
Scientific Tools and Resources
ALS researchers worldwide have access to a range of critical tools ranging from biospecimens to genomic datasets to stem cells with no strings attached.
Target ALS offers the pharma/biotech industry access to its funding and resources to promote collaborative research projects across academia and industry and to seed ALS drug discovery programs in the industry. By fostering partnerships, we are accelerating progress toward effective treatments for ALS.
Independent Grant Review
All funding decisions are reviewed and ultimately decided by a conflict-free Independent Review Committee.
No Intellectual Property Restrictions
To further foster collaboration and encourage the free flow of information, Target ALS has no intellectual property (IP) restrictions on data generated by its funded research projects or through use of its scientific tools and resources.
Networking and Communication
Target ALS fosters ongoing networking and communication and hosts a range of scientific meetings. During our annual scientific meeting in Cambridge, Mass., scientists, foundations, venture capitalists, industry leaders and donors convene to coordinate, communicate and collaborate around leading research ideas.
Join Us to Change the Prognosis for Patients
In just a few years time, the Target ALS Innovation Ecosystem has produced the first therapeutic options with a strong biologic rationale. For the first time in the 150 year history of the disease, we face a historic opportunity to radically change the prognosis for patients.
Over the next several years and with your support, Target ALS will expand the ALS Innovation Ecosystem to effectively drive the development of new therapies and their rapid translation into the clinic. Learn more about our new plan to produce the first set of transformative breakthroughs on behalf of patients.
Together, we can achieve historic breakthroughs and change the prognosis for patients.
We invite you to join us.